Bimagrumab

• Description:

  Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].

• Product Name Alternative:

  Anti-ACVR2B Reference Antibody; BYM338

• UNSPSC:

  12352203

• Target:

  TGF-β Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  TGF-beta/Smad

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/bimagrumab.html

• Purity:

  99.31

• Solubility:

  H2O

• Smiles:

  [Bimagrumab]

• Molecular Weight:

  (142.78 kDa)

• References & Citations:

  [1]Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4 (1) :e2033457. |[2]Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34 (4) :606-18.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 3

• Isoform:

  ACVR2A; ACVR2B

• CAS Number:

  [1356922-05-8]